526 件 ・ 関連度順
概要と使いどころ
Capture durable project memory from work, debates, debugging discoveries, learned conventions, deferred options, and session outcomes. Load when the user says remember this, save this learning, record what happened, update project memory, or preserve context for future agents.
日本語の概要は準備中です。原文の説明を表示しています。
Designs cytosine (CBE, C-to-T) and adenine (ABE, A-to-G) base-editor guides by positioning the target base at the activity-peak of the editing window (protospacer positions ~5-7, PAM-distal numbering), minimizing bystander edits for product purity, reading dinucleotide context (APOBEC1 TC favored / GC disfavored), and selecting the editor variant (BE4max, ABEmax, ABE8e, YE1/SECURE, TadCBE, CGBE, SpG/SpRY-BE). Covers knockout by premature stop (CRISPR-STOP/iSTOP) and splice-site disruption, the three off-target classes (Cas-dependent, Cas-independent DNA, RNA), outcome prediction (BE-Hive/DeepBE), and the base-vs-prime-vs-HDR decision. Use when installing a transition mutation without a double-strand break, knocking out a gene without indels, or choosing CBE vs ABE. Generic guide scoring, prime editing, and HDR donors are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and ranks guide RNAs (sgRNAs) for CRISPR-Cas9/Cas12a gene knockout by scanning a target for PAM sites (NGG SpCas9, NNGRRT SaCas9, TTTV Cas12a, NG SpCas9-NG, near-PAMless SpRY), enumerating candidate spacers, applying hard filters (Pol-III TTTT terminator, 5' G, GC), ranking on-target activity with the context-appropriate model (Rule Set 2/Azimuth for U6/lentiviral, CRISPRscan for T7/embryo, DeepHF for high-fidelity variants, DeepCpf1 for Cas12a), and predicting the indel/frameshift outcome (Bae out-of-frame score, inDelphi, FORECasT, Lindel). Use when selecting sgRNAs to knock out a gene, choosing a nuclease/PAM for a constrained locus, picking which exon to target, or shortlisting guides before an off-target check. Off-target specificity, base/prime editing, and HDR donors are separate skills.
日本語の概要は準備中です。原文の説明を表示しています。
Quantifies CRISPR editing outcomes with CRISPResso2 (Clement 2019 Nat Biotechnol) across Cas9-nuclease (indels, HDR), CBE and ABE base editors (target conversion + bystander), and prime editor (pegRNA-templated) modes. Covers single-amplicon (CRISPResso), multi-sample batch (CRISPRessoBatch), pooled-amplicon (CRISPRessoPooled), WGS off-target (CRISPRessoWGS), and sample-comparison (CRISPRessoCompare) workflows; quantification-window math that controls what is called edited; substitution-vs-indel diagnostic to distinguish BE from Cas9 contamination; MMEJ deletion pattern interpretation; allele-frequency tables; and failure modes from amplicon misalignment or contamination. Use when quantifying editing from amplicon sequencing, choosing CRISPResso mode by design, distinguishing intended edits from bystanders and indel byproducts, debugging low-alignment runs, or generating publication-grade editing reports.
日本語の概要は準備中です。原文の説明を表示しています。
Estimate causal effects of an exposure on an outcome from GWAS summary statistics using genetic instruments. Implements IVW (fixed/random), MR-Egger, weighted median/mode, MR-RAPS, CAUSE, GSMR-HEIDI, MR-PRESSO, MVMR, MR-Clust, LCV, and LHC-MR via TwoSampleMR, MendelianRandomization, MR-PRESSO, cause, and lhcMR. Use when testing causal direction between traits, evaluating drug-target effects via cis-pQTL/cis-eQTL, performing multivariable mediation MR, distinguishing causation from correlated horizontal pleiotropy, or producing STROBE-MR-compliant sensitivity batteries.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Decompose total effects into direct and indirect paths through mediators using mediation, CMAverse 4-way, HIMA/HIMA2 high-dimensional, BAMA, two-step / MVMR mediation, or double-ML medDML. Use when testing whether a molecular phenotype (expression, methylation, protein) mediates a treatment-outcome relationship, decomposing exposure-mediator interaction via VanderWeele 4-way, screening high-dimensional EWAS mediators, or running MR-based mediation when sequential ignorability is implausible.
日本語の概要は準備中です。原文の説明を表示しています。
Estimate bivariate genetic correlation (rg) between traits from GWAS summary statistics or individual-level genotypes using cross-trait LDSC, HDL, LAVA, rho-HESS, GREML-bivariate, Popcorn, and HDL-L. Use when quantifying shared genetic architecture between two traits, screening MR validity before causal inference, distinguishing global from locus-level rg, estimating trans-ancestry rg, separating partial from full causation via LCV gcp, or producing a STROBE-MR-compliant cross-trait sensitivity battery. Cross-trait LDSC intercept absorbs sample overlap and is NOT a bias; HDL is biased under sample overlap above ~5%. High rg between exposure and outcome motivates CHP-aware MR sensitivity (CAUSE, LHC-MR).
日本語の概要は準備中です。原文の説明を表示しています。
Predicts whether a DNA variant alters mRNA splicing using sequence-based deep-learning tools — SpliceAI (10kb context dilated CNN, clinical default), Pangolin (multi-tissue), MMSplice (modular per-region CNN with calibrated ΔPSI), SpliceTransformer/TrASPr (tissue-aware transformers), SpliceVault (empirical 300K-RNA lookup of likely mis-splicing outcomes), CADD-Splice (composite score). Applies the ClinGen SVI 2023 framework for ACMG/AMP variant interpretation (PVS1, PP3, BP4 evidence codes), HGVS splicing nomenclature (c.123+1G>A, c.123-3T>G, r.spl?), extended-window scoring for deep-intronic pseudoexons, tissue-specific predictions, branchpoint variant detection (BPHunter, LaBranchoR), and splice-switching ASO design. Use when interpreting splice impact of clinical variants, prioritizing VUS, identifying deep-intronic pathogenic variants, or designing ASOs.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill to set proper expectations on how a DataQ challenge is actually reviewed. Covers state vs federal authority, typical timelines, and common review outcomes.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill when the user asks how to design or improve a fleet safety scorecard — what KPIs to track, how to weight them, telematics signals vs document compliance vs roadside outcomes, monthly cadence, driver-facing vs admin-facing dashboards, gamification considerations, peer-comparison metrics, and how a scorecard ties to insurance premiums + retention. Reference SMS Methodology v3.20 for industry-standard weights.
日本語の概要は準備中です。原文の説明を表示しています。
Use this skill when the user asks about accident claims management — first-notice-of-loss procedures, working with insurance adjusters, claim severity classification, subrogation, claim closure timelines, and how to influence claim outcomes. Different from accident-investigation-playbook (which covers facts); this covers the insurance + claim side.
日本語の概要は準備中です。原文の説明を表示しています。
Retrieve and analyze simulation results from a Coval run. Use when user wants to review evaluation outcomes or debug agent behavior.
日本語の概要は準備中です。原文の説明を表示しています。
Executive coaching skill that helps you plan your 2026 using research-backed process goals. Guides you through discovery questions, creates outcome goals, converts them to daily behaviors, and sets up accountability systems. Use when you want to plan your year, set goals, or need a coach to help you stay focused.
日本語の概要は準備中です。原文の説明を表示しています。
Generate professional clinical decision support (CDS) documents for pharmaceutical and clinical research settings, including patient cohort analyses (biomarker-stratified with outcomes) and treatment recommendation reports (evidence-based guidelines with decision algorithms). Supports GRADE evidence grading, statistical analysis (hazard ratios, survival curves, waterfall plots), biomarker integration, and regulatory compliance. Outputs publication-ready LaTeX/PDF format optimized for drug development, clinical research, and evidence synthesis.
日本語の概要は準備中です。原文の説明を表示しています。
AEO — Agent 效果运营平台。自动发现 Agent 效果漂移、诊断根因、运行 AI 数据闭环工具链，给出 AI 效果优化方案。Measure agent performance, attribute outcomes, track quality trends, optimize cost, and monitor SLAs.
日本語の概要は準備中です。原文の説明を表示しています。
Generate a session report with token usage estimates, work summary, and outcomes
日本語の概要は準備中です。原文の説明を表示しています。
Decision tree analysis for complex decision-making across all domains. Use when user needs to evaluate multiple options with uncertain outcomes, assess risk/reward scenarios, or structure choices systematically. Applicable to business, investment, personal decisions, operations, career choices, product strategy, and any situation requiring structured evaluation. Triggers include decision tree, should I, what if, evaluate options, compare alternatives, risk analysis.
日本語の概要は準備中です。原文の説明を表示しています。
AI Agent Prediction Arena - Predict Kalshi market outcomes, compete for accuracy
日本語の概要は準備中です。原文の説明を表示しています。
Audit or design server-side indexes, directories, reputations, or aggregates that are DERIVED from traffic a platform witnesses (chain heads, run verdicts, heartbeats, publish activity) so that consent gates the derivation, not merely the read: no shadow index over non-consenting principals, post-consent-only evidence windows, retention bounds and delete-propagation into derived rows, activity-oracle threat modeling, and audit-logged ranking discretion. Use when building a capability directory / whois from witnessed activity, a reputation ledger from settled outcomes, vitals aggregation across tenants, or any "the yellow pages can't lie because they index signatures" feature. Keywords: shadow index, derived index, consent gates derivation, activity oracle, phone book not a log, delist propagation, ranking weight audit, k-anonymous aggregate, subpoena surface. NOT for the consent-screen UX and scope-ladder mechanics themselves (use local-first-tenancy-boundary), reputation scoring math and Sybil economics (use agent-identity-continuity-reputation), or discovery-layer architecture L1/L2/L3 (use agent-discovery-directories-guilds).
日本語の概要は準備中です。原文の説明を表示しています。
Design or review a declared control-command profile and its verb/backend lifecycle matrix. Distinguish policy denial, unsupported capability, delivery acknowledgement, independently observed effect, and unknown outcome; bind authorization to principal, target, scope, current policy, expiry, and fencing epoch. NOT for claiming runtime correctness, proving an adapter from declarations, or approving a control-panel button without independent runtime evidence.
日本語の概要は準備中です。原文の説明を表示しています。
Design and audit a pricing function for variable-cost agent labor. Choose among per-seat, metered, credits, hybrid, and outcome pricing; name buyer value and cost metrics separately; calculate a reproducible cost floor; require pre-commitment guardrails; and stress-test declared personas. Use for offline pricing-design evidence, not billing implementation or runtime control. NOT for production billing, payment collection, or runtime spend enforcement.
日本語の概要は準備中です。原文の説明を表示しています。